Bevacizumab (anti‐VEGF) normalizes tumor vasculature to enhance T cell infiltration; [49, 50] paired with galunisertib, it may suppress hmmyCAF TGF‐β signaling, disrupting collagen XV barriers and POSTN‐checkpoint interactions. Here, VEGFA is linked to neoplasm.